Equity Research Laboratory Analytical Instruments

Should You Buy Bionano Genomics, Inc. Stock in 2026?

By CirclFi Research Team · · 6/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Bionano Genomics, Inc. (BNGO) occupies a solid middle-ground position with a Quality of Company score of 5.9/10. At the current market price of $1.13, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 5 of 6 CirclFi valuation models project upside for Bionano Genomics, Inc. (BNGO) at $1.13 — the model consensus leans bullish, with a Quality Score of 5.9/10 and Value-Trap risk of 39/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 5 of 6 models see upside — majority bullish
  • Quality Score: 5.9/10 — Moderate — mixed signals
  • Value Trap Risk: 39/100 — Low — manageable risk
  • Fair Value Range: $0.21 – $4.67 (2147% spread)

Bullish Models

5 / 6

Bearish Models

1 / 6

Quality Score

5.9 /10

Moderate — mixed signals

Value Trap Risk

39 /100
Low

Low — manageable risk

Model Consensus

6 /13
Active Models

Avg. confidence: 22%

Investment Thesis

The Bull Case

Target: $4.67 (+315.5% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, 5 of 6 models identify upside from $1.13 to a composite fair value of $2.93, indicating the market hasn't fully priced in Bionano Genomics, Inc.'s earnings power.
  • According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model targets a fair value of $4.67 (+315.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $0.21 (-81.5%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.21 (-81.5%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +397.0% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

Peer Benchmarking

MTD Mettler-Toledo Inter
9.2
AVTR Avantor, Inc.
9.2
BRKR Bruker Corporation
8.5
TXG 10x Genomics, Inc.
8.2
BIO Bio-Rad Laboratories
8.1

Valuation Divergence

Spread

2147%

Fair Value Range

$0.21 – $4.67

A 2147% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Sentiment SOTP

$4.67 (+315.5%)

Most Bearish

Bayesian DCF

$0.21 (-81.5%)

Key Risk Factors

Model Disagreement

2147% spread signals high variance in projections.

Macro/Sector Risk

Laboratory Analytical Instruments headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View BNGO Data Page →

The Bottom Line

The convergence of 5.9/10 quality, multi-model undervaluation (5/6 bullish, +160.7% avg. upside), and a composite fair value of $2.93 vs. $1.13 current price makes Bionano Genomics, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.

These are quantitative model outputs, not investment recommendations. Bionano Genomics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy BNGO stock right now?

Based on CirclFi's multi-model analysis, 5 of 6 models see upside for BNGO at $1.13. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.9/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Bionano Genomics, Inc.?

Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (2147% spread), signaling high uncertainty; general market and sector-specific risks affecting Laboratory Analytical Instruments companies. Always diversify and consult a financial advisor.

How does BNGO compare to its competitors?

Among Laboratory Analytical Instruments peers, BNGO holds a Quality Score of 5.9/10. Comparable companies include MTD (QOC 9.2), AVTR (QOC 9.2), BRKR (QOC 8.5). The relative ranking helps investors identify whether BNGO offers better fundamental quality than alternatives in the same sector.

Is BNGO a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BNGO's Quality Score of 5.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy BNGO at?

CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $0.21 to $4.67. At $1.13, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for BNGO.

View BNGO Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →